{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:09:14Z","timestamp":1758892154276,"version":"3.37.3"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","award":["10.13039\/100004337"],"award-info":[{"award-number":["10.13039\/100004337"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Menarini Silicon Biosystems, Janssen Diagnostics"},{"name":"Roche, Menarini Silicon Biosystems, Janssen Diagnostics","award":["NCT03065621"],"award-info":[{"award-number":["NCT03065621"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1093\/annonc\/mdz404","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T11:25:50Z","timestamp":1569497150000},"page":"1677-1681","source":"Crossref","is-referenced-by-count":1,"title":["Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?"],"prefix":"10.1016","volume":"30","author":[{"given":"M.","family":"Brand\u00e3o","sequence":"first","affiliation":[]},{"given":"C.","family":"Coens","sequence":"additional","affiliation":[]},{"given":"M.","family":"Ignatiadis","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"19","key":"10.1093\/annonc\/mdz404_bb0010","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdz404_bb0015","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz298","article-title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","author":"Ferreira","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz404_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz289","article-title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen\u2014To Offer More? (aTTom) trial","author":"Bartlett","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz404_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz404_bb0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2005.04.5393","article-title":"Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients\u2014The International Breast Cancer Study Group Trial VIII","volume":"25","author":"Bernhard","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz404_bb0035","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.2015.64.3866","article-title":"Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the mind-body study","volume":"34","author":"Ganz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz404_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international Consensus Guidelines for the primary therapy of early breast cancer 2019","author":"Burstein","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz404_bb0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer: ASCO Clinical Practice Guideline Focused Update","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1093\/annonc\/mdz404_bb0050","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2017.76.4258","article-title":"Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor\u2013positive breast cancer treated with 5 years of endocrine therapy: CTS5","volume":"36","author":"Dowsett","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz404_bb0055","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamaoncol.2017.5524","article-title":"Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial","volume":"4","author":"Sestak","year":"2018","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1093\/annonc\/mdz404_bb0060","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.19.00945","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO Clinical Practice Guideline Update\u2014Integration of Results From TAILORx","volume":"37","author":"Andre","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdz404_bb0065","article-title":"Abstract GS3-03: effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24, 912 women","volume":"79","author":"Gray","year":"2019","journal-title":"Cancer Res"},{"issue":"14","key":"10.1093\/annonc\/mdz404_bb0070","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djt146","article-title":"Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13\/IL17BR biomarker","volume":"105","author":"Sgroi","year":"2013","journal-title":"JNCI J. Natl. Cancer Inst"},{"issue":"11","key":"10.1093\/annonc\/mdz404_bb0075","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1158\/0008-5472.CAN-18-3402","article-title":"Promises and pitfalls of using liquid biopsy for precision medicine","volume":"79","author":"Rossi","year":"2019","journal-title":"Cancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdz404_bb0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","article-title":"Quality of life of postmenopausal women in the ATAC (\u201cArimidex\u201d, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for early breast cancer","volume":"100","author":"Cella","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1093\/annonc\/mdz404_bb0085","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2005.03.3654","article-title":"Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer","volume":"24","author":"Fallowfield","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdz404_bb0090","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","article-title":"Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial","volume":"26","author":"Mamounas","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdz404_bb0095","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","article-title":"Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials","volume":"16","author":"Bernhard","year":"2015","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1093\/annonc\/mdz404_bb0100","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial","volume":"34","author":"Ribi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz404_bb0105","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JCO.2017.75.7500","article-title":"Quality of life from Canadian Cancer Trials Group MA.17R: a randomized trial of extending adjuvant letrozole to 10 years","volume":"36","author":"Lemieux","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz404_bb0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(17)30715-5","article-title":"Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Colleoni","year":"2018","journal-title":"Lancet Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdz404_bb0115","article-title":"Abstract GS6-03: symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): tAILORx patient-reported outcomes results","volume":"79","author":"Wagner","year":"2019","journal-title":"Cancer Res"},{"issue":"14","key":"10.1093\/annonc\/mdz404_bb0120","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1200\/JCO.2013.51.2483","article-title":"Quality of Life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer","volume":"32","author":"Maunsell","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420326028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420326028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz404\/30246310\/mdz404.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz404\/30246310\/mdz404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:47:52Z","timestamp":1624700872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420326028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0923753420326028"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz404","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}